Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,438
  • Shares Outstanding, K 12,299
  • Annual Sales, $ 28,540 K
  • Annual Income, $ -39,260 K
  • EBIT $ -44 M
  • EBITDA $ -42 M
  • 60-Month Beta 0.91
  • Price/Sales 0.41
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.01
  • Most Recent Earnings $-0.67 on 11/14/25
  • Next Earnings Date 11/21/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 341.80% (-5.45%)
  • Historical Volatility 69.63%
  • IV Percentile 51%
  • IV Rank 22.75%
  • IV High 1,329.79% on 05/16/25
  • IV Low 50.92% on 10/16/25
  • Expected Move (DTE 10) 0.0850 (9.14%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 331
  • Open Int (30-Day) 322
  • Expected Range 0.8450 to 1.0150

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +53.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9300 +4.30%
on 12/08/25
1.4800 -34.46%
on 11/12/25
-0.4100 (-29.71%)
since 11/07/25
3-Month
0.9300 +4.30%
on 12/08/25
2.4900 -61.04%
on 09/11/25
-1.3700 (-58.55%)
since 09/09/25
52-Week
0.9300 +4.30%
on 12/08/25
3.9000 -75.13%
on 12/10/24
-2.9200 (-75.06%)
since 12/09/24

Most Recent Stories

More News
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

CASI : 0.9700 (+4.30%)
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

BEIJING, CN / ACCESS Newswire / April 3, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI, "CASI"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics...

CASI : 0.9700 (+4.30%)
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.9700 (+4.30%)
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

BEIJING, CHINA / ACCESSWIRE / January 6, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and...

CASI : 0.9700 (+4.30%)
Nasdaq Futures Fall as Micron’s Sales Outlook Disappoints, U.S. GDP Data and Nike Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU24) are trending down -0.23% this morning as an underwhelming sales forecast from chipmaker Micron weighed on sentiment, while investors awaited a flurry of U.S....

WHR : 75.01 (-1.38%)
AAPL : 278.63 (+0.27%)
HMB.S.DX : 172.900 (-0.55%)
MKC : 63.60 (+0.47%)
NQU24 : 19,808.01s (-0.21%)
USB : 51.41 (+0.29%)
IP : 38.51 (-1.41%)
MU : 244.38 (-1.03%)
NKE : 63.65 (+0.17%)
CASI : 0.9700 (+4.30%)
LEVI : 21.64 (unch)
AYI : 373.41 (+0.31%)
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.9700 (+4.30%)
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

CASI : 0.9700 (+4.30%)
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

CASI : 0.9700 (+4.30%)
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

CASI : 0.9700 (+4.30%)
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

CASI : 0.9700 (+4.30%)

Business Summary

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic...

See More

Key Turning Points

3rd Resistance Point 1.1298
2nd Resistance Point 1.0899
1st Resistance Point 1.0099
Last Price 0.9700
1st Support Level 0.8900
2nd Support Level 0.8501
3rd Support Level 0.7701

See More

52-Week High 3.9000
Fibonacci 61.8% 2.7655
Fibonacci 50% 2.4150
Fibonacci 38.2% 2.0645
Last Price 0.9700
52-Week Low 0.9300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar